| Bioactivity | BHEPN is an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). BHEPN has inhibition of VEGFR-2 with an IC50 value of 0.320 μM. BHEPN also exhibits remarkable cytotoxic effects against HepG2 and MCF-7 cancer cell lines, with IC50 values of 0.19 μM and 1.18 μM, respectively. BHEPN can be used for anticancer research[1]. |
| Target | IC50: 0.320 μM (VEGFR-2); 0.19 μM (HepG2); 1.18 μM (MCF-7) |
| Name | BHEPN |
| Formula | C21H17BrN4O2 |
| Molar Mass | 437.29 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Eissa IH, et al. Exploring the anticancer properties of a new nicotinamide analogue: Investigations into in silico analysis, antiproliferative effects, selectivity, VEGFR-2 inhibition, apoptosis induction, and migration suppression. Pathol Res Pract. 2023 Dec;252:154924. |